Hospital
VHS Harper-Hutzel Hospital INC
VHS Harper-Hutzel Hospital INC was paid $76.70M by Medicaid between Jan 2018 and Dec 2024, across 448 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoVHS HARPER-HUTZEL HOSPITAL INC
DETROIT, MI 48201
DETROIT, MI 48201
33aNPI1427360700assigned 07/02/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$76.70M
24GClaims1,864,690
24DCodes billed448
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#14 of 86
Median peer was paid$21.55M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 313,836 | $12.00M | |
| 2019 | 324,644 | $11.68M | |
| 2020 | 278,659 | $9.72M | |
| 2021 | 295,302 | $12.71M | |
| 2022 | 245,768 | $11.87M | |
| 2023 | 228,802 | $10.56M | |
| 2024incomplete | 177,679 | $8.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 44,154 | 41,427 | $8.86M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 10% | 126,518 | 107,141 | $7.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.8% | 20,983 | 19,370 | $6.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 54,401 | 48,666 | $6.55M |
| G0378 | Hospital observation service, per hour | 4.7% | 8,405 | 7,797 | $3.59M |
| 27447 | 4.4% | 524 | 520 | $3.36M | |
| 36512 | 2.6% | 4,332 | 3,751 | $2.01M | |
| 36556 | 2.5% | 1,951 | 1,720 | $1.95M | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.5% | 5,249 | 5,202 | $1.91M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.5% | 3,941 | 3,894 | $1.91M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 22,731 | 20,761 | $1.62M |
| P9016 | Red blood cells, leukocytes reduced, each unit | 1.9% | 5,136 | 4,482 | $1.49M |
436 more codes
| 27130 | 1.8% | 204 | $1.42M | |
| 59025 | Fetal non-stress test | 1.8% | 17,362 | $1.36M |
| 93458 | 1.6% | 879 | $1.25M | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.4% | 1,209 | $1.09M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 1,827 | $941K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.1% | 7,350 | $858K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.1% | 15,724 | $841K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 1.1% | 1,993 | $806K |
| C1776 | Joint device (implantable) | 1.0% | 1,254 | $803K |
| 58558 | <1% | 542 | $665K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,127 | $626K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,102 | $590K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,263 | $587K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,080 | $514K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,529 | $466K |
| 76801 | <1% | 8,705 | $453K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,824 | $441K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,124 | $429K |
| 43235 | <1% | 1,215 | $428K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,123 | $409K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,839 | $406K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,756 | $406K |
| 58661 | <1% | 143 | $371K | |
| 72141 | <1% | 2,292 | $364K | |
| 76830 | Ultrasound, transvaginal | <1% | 6,289 | $354K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,829 | $352K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,455 | $340K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 618 | $334K |
| 95910 | <1% | 2,455 | $334K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,180 | $295K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,879 | $295K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26,806 | $284K |
| 94060 | <1% | 2,076 | $281K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26,795 | $277K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,219 | $270K |
| 72156 | <1% | 657 | $245K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 774 | $244K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,826 | $243K |
| 95911 | <1% | 942 | $231K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,825 | $225K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,864 | $224K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,635 | $221K |
| 86900 | <1% | 31,391 | $210K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 944 | $202K |
| 58300 | <1% | 942 | $198K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,873 | $197K |
| 99218 | <1% | 688 | $190K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,811 | $182K |
| 94726 | <1% | 3,376 | $176K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,461 | $175K |
| 80061 | Lipid panel | <1% | 2,150 | $166K |
| 73221 | <1% | 979 | $144K | |
| 74178 | <1% | 761 | $141K | |
| 93970 | <1% | 1,418 | $139K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 299 | $128K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 909 | $128K |
| 86902 | <1% | 2,228 | $124K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,019 | $118K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 22,062 | $116K |
| 86780 | <1% | 16,109 | $114K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,231 | $113K |
| 76770 | <1% | 1,736 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48,421 | $102K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,508 | $96K |
| 97162 | <1% | 1,875 | $90K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,980 | $89K |
| 97166 | <1% | 1,996 | $88K | |
| 76536 | <1% | 1,642 | $87K | |
| 93971 | <1% | 1,604 | $87K | |
| 71250 | <1% | 1,434 | $83K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,538 | $83K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,478 | $79K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 6,826 | $76K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,694 | $73K |
| 95816 | <1% | 518 | $72K | |
| 86923 | <1% | 2,972 | $67K | |
| 37225 | <1% | 12 | $63K | |
| 86870 | <1% | 1,004 | $62K | |
| 95819 | <1% | 496 | $58K | |
| 77080 | <1% | 970 | $57K | |
| 71271 | <1% | 996 | $55K | |
| 76825 | <1% | 227 | $55K | |
| 93975 | <1% | 545 | $54K | |
| 73700 | <1% | 859 | $52K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 127 | $51K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,641 | $51K |
| 95908 | <1% | 394 | $50K | |
| 76813 | <1% | 1,253 | $49K | |
| 80053 | Comprehensive metabolic panel | <1% | 19,502 | $47K |
| 72100 | <1% | 1,752 | $44K | |
| 87625 | <1% | 3,542 | $43K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 720 | $41K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 319 | $41K |
| 72110 | <1% | 1,012 | $40K | |
| 73560 | <1% | 1,523 | $40K | |
| 85027 | <1% | 49,577 | $40K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 585 | $38K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,557 | $38K |
| 93922 | <1% | 987 | $38K | |
| 83735 | <1% | 35,958 | $37K | |
| 70486 | <1% | 627 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 762 | $35K |
| 67113 | <1% | 13 | $35K | |
| 70491 | <1% | 299 | $34K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,612 | $32K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,897 | $32K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 13 | $32K |
| 36430 | <1% | 235 | $31K | |
| 73130 | <1% | 2,711 | $30K | |
| 11981 | <1% | 141 | $30K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,997 | $30K |
| 10060 | <1% | 303 | $30K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,403 | $30K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 68 | $30K |
| 93017 | <1% | 2,022 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 11,993 | $29K |
| 86850 | <1% | 31,079 | $29K | |
| 72158 | <1% | 186 | $29K | |
| 86922 | <1% | 2,272 | $27K | |
| 73030 | <1% | 2,555 | $27K | |
| 73562 | <1% | 1,962 | $26K | |
| 81025 | <1% | 26,511 | $25K | |
| 86829 | <1% | 824 | $23K | |
| 81401 | <1% | 520 | $22K | |
| 75716 | <1% | 44 | $22K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 513 | $22K |
| 82951 | <1% | 2,971 | $22K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,321 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,917 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,720 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,163 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,894 | $19K |
| 82728 | <1% | 5,691 | $19K | |
| 58670 | <1% | 17 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,604 | $18K |
| 72170 | <1% | 717 | $17K | |
| 81003 | <1% | 19,218 | $17K | |
| J2704 | Injection, propofol, 10 mg | <1% | 25,600 | $17K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 188 | $17K |
| 84484 | <1% | 13,816 | $16K | |
| 87480 | <1% | 2,976 | $16K | |
| 84702 | <1% | 9,850 | $15K | |
| 93454 | <1% | 12 | $15K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,070 | $15K |
| 82962 | <1% | 10,249 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,635 | $15K |
| 86762 | <1% | 6,379 | $14K | |
| 77001 | <1% | 2,031 | $14K | |
| 72146 | <1% | 103 | $14K | |
| 73564 | <1% | 1,787 | $14K | |
| 87510 | <1% | 2,852 | $14K | |
| 72131 | <1% | 315 | $14K | |
| 57454 | <1% | 110 | $13K | |
| 87340 | <1% | 10,360 | $13K | |
| 0012A | <1% | 379 | $13K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,282 | $13K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14,982 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,482 | $13K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 376 | $12K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,145 | $12K |
| 86901 | <1% | 31,116 | $12K | |
| 94618 | <1% | 865 | $12K | |
| 73502 | <1% | 1,250 | $12K | |
| 86833 | <1% | 98 | $12K | |
| 86832 | <1% | 98 | $12K | |
| 95708 | <1% | 73 | $12K | |
| 76881 | <1% | 174 | $11K | |
| 94010 | <1% | 1,599 | $11K | |
| 81002 | <1% | 17,267 | $11K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 322 | $10K |
| 83021 | <1% | 4,782 | $10K | |
| 87660 | <1% | 2,040 | $10K | |
| 86803 | <1% | 2,519 | $10K | |
| 11976 | <1% | 28 | $10K | |
| 0011A | <1% | 425 | $10K | |
| 76937 | <1% | 2,253 | $10K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 28 | $10K |
| 72050 | <1% | 234 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 32,735 | $9K |
| 72040 | <1% | 410 | $9K | |
| 82330 | <1% | 4,444 | $9K | |
| 87467 | <1% | 2,669 | $9K | |
| 95700 | <1% | 67 | $9K | |
| 91200 | <1% | 132 | $9K | |
| 64447 | <1% | 214 | $9K | |
| 66982 | <1% | 12 | $8K | |
| 73630 | <1% | 2,001 | $8K | |
| 58301 | <1% | 42 | $8K | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 481 | $8K |
| 29881 | <1% | 13 | $8K | |
| 87077 | <1% | 5,655 | $8K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,144 | $8K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,675 | $8K |
| 81001 | <1% | 23,850 | $8K | |
| 88307 | <1% | 786 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,722 | $7K |
| 93880 | <1% | 89 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 21,102 | $7K |
| 87081 | <1% | 5,033 | $7K | |
| 82607 | <1% | 1,915 | $7K | |
| 70496 | <1% | 54 | $7K | |
| 0002A | <1% | 183 | $7K | |
| 73610 | <1% | 1,414 | $6K | |
| 83880 | <1% | 3,665 | $6K | |
| 0001A | <1% | 198 | $6K | |
| 97161 | <1% | 51 | $6K | |
| 73110 | <1% | 725 | $6K | |
| 99152 | <1% | 1,881 | $6K | |
| 82565 | <1% | 5,122 | $6K | |
| 90686 | <1% | 367 | $6K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 3,301 | $6K |
| A9270 | Non-covered item or service | <1% | 84,670 | $5K |
| 93325 | <1% | 1,332 | $5K | |
| 76870 | <1% | 169 | $5K | |
| 83690 | <1% | 10,052 | $5K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 4,106 | $5K |
| 87799 | <1% | 374 | $5K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 24 | $5K |
| 85610 | <1% | 12,578 | $5K | |
| 90674 | <1% | 286 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,045 | $5K |
| 99407 | <1% | 82 | $5K | |
| 97116 | <1% | 2,455 | $5K | |
| 85384 | <1% | 1,089 | $5K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 551 | $4K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 120 | $4K |
| 85730 | <1% | 11,998 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 366 | $4K |
| 87040 | <1% | 1,799 | $4K | |
| 76820 | <1% | 3,779 | $4K | |
| 93308 | <1% | 67 | $4K | |
| 82248 | <1% | 4,621 | $4K | |
| 86787 | <1% | 1,425 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,922 | $3K |
| 95886 | <1% | 4,543 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,075 | $3K |
| 83605 | <1% | 2,922 | $3K | |
| 82105 | <1% | 893 | $3K | |
| 84100 | <1% | 4,032 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,877 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 12,023 | $3K |
| 80197 | <1% | 641 | $3K | |
| 84460 | <1% | 7,727 | $3K | |
| 94729 | <1% | 3,324 | $3K | |
| 84450 | <1% | 7,728 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,970 | $3K |
| 93320 | <1% | 857 | $3K | |
| 84425 | <1% | 438 | $3K | |
| 84439 | <1% | 1,013 | $3K | |
| 72197 | <1% | 13 | $2K | |
| 84703 | <1% | 4,964 | $2K | |
| 72070 | <1% | 104 | $2K | |
| 83540 | <1% | 1,666 | $2K | |
| 80177 | <1% | 891 | $2K | |
| 82570 | <1% | 3,094 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,628 | $2K |
| 73120 | <1% | 74 | $2K | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 1,887 | $2K |
| G0008 | Administration of influenza virus vaccine | <1% | 339 | $2K |
| 88312 | <1% | 1,757 | $2K | |
| 84132 | <1% | 5,674 | $2K | |
| 84075 | <1% | 5,693 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 267 | $2K |
| 87070 | <1% | 1,542 | $2K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 328 | $2K |
| 86140 | <1% | 1,580 | $2K | |
| 88304 | <1% | 1,674 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 509 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 783 | $2K |
| 88342 | <1% | 497 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,364 | $2K |
| 86703 | <1% | 2,096 | $2K | |
| 83921 | <1% | 333 | $2K | |
| 86235 | <1% | 276 | $1K | |
| 86038 | <1% | 552 | $1K | |
| 85014 | <1% | 4,787 | $1K | |
| 74018 | <1% | 144 | $1K | |
| 74022 | <1% | 519 | $1K | |
| 87631 | <1% | 1,217 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,224 | $1K |
| 84295 | <1% | 4,237 | $1K | |
| 80051 | <1% | 723 | $1K | |
| 74021 | <1% | 183 | $1K | |
| 84156 | <1% | 2,740 | $1K | |
| 82247 | <1% | 5,040 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,451 | $1K |
| 80074 | <1% | 149 | $1K | |
| 85379 | <1% | 2,598 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,756 | $1K |
| 84146 | <1% | 154 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 1,223 | $1K |
| 83615 | <1% | 1,813 | $974.57 | |
| 76821 | <1% | 1,964 | $971.95 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,456 | $958.15 |
| 64415 | <1% | 93 | $951.27 | |
| 83970 | <1% | 113 | $941.43 | |
| 82542 | <1% | 4,086 | $924.76 | |
| 82150 | <1% | 1,355 | $916.11 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,035 | $905.37 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,178 | $892.61 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,026 | $820.61 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 222 | $802.90 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 56 | $802.05 |
| J3415 | Injection, pyridoxine hcl, 100 mg | <1% | 1,064 | $788.44 |
| 74019 | <1% | 155 | $764.78 | |
| 83090 | <1% | 209 | $711.06 | |
| 82803 | <1% | 312 | $678.92 | |
| 82550 | <1% | 597 | $677.65 | |
| 87341 | <1% | 235 | $666.87 | |
| 88341 | <1% | 31 | $639.20 | |
| 87102 | <1% | 377 | $638.75 | |
| 86360 | <1% | 40 | $631.53 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 482 | $630.93 |
| 82784 | <1% | 190 | $620.79 | |
| 80076 | <1% | 341 | $579.64 | |
| 96367 | <1% | 25 | $548.89 | |
| 99385 | <1% | 12 | $522.46 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,832 | $507.81 |
| 88302 | <1% | 344 | $507.32 | |
| 86359 | <1% | 40 | $506.58 | |
| 87205 | <1% | 1,234 | $493.88 | |
| 73590 | <1% | 117 | $479.63 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,066 | $465.05 |
| 90715 | <1% | 3,629 | $452.45 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 873 | $452.31 |
| 84550 | <1% | 433 | $434.09 | |
| 85652 | <1% | 1,197 | $425.54 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,471 | $412.92 |
| 82746 | <1% | 136 | $382.08 | |
| 85018 | <1% | 522 | $366.47 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 559 | $357.96 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 967 | $349.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,263 | $325.29 |
| 86357 | <1% | 27 | $318.78 | |
| 86355 | <1% | 27 | $318.78 | |
| 84466 | <1% | 102 | $317.05 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 276 | $271.35 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 3,349 | $266.63 |
| 70498 | <1% | 13 | $258.48 | |
| 73080 | <1% | 44 | $258.14 | |
| 87075 | <1% | 117 | $245.73 | |
| 83516 | <1% | 53 | $239.56 | |
| 86334 | <1% | 37 | $239.19 | |
| C9399 | Unclassified drugs or biologicals | <1% | 82 | $237.16 |
| 85046 | <1% | 214 | $235.23 | |
| 86706 | <1% | 120 | $225.06 | |
| 85347 | <1% | 438 | $219.59 | |
| 83550 | <1% | 195 | $213.50 | |
| 83001 | <1% | 25 | $211.47 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $206.85 |
| 80235 | <1% | 51 | $201.05 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 76 | $197.92 |
| 76376 | <1% | 203 | $180.16 | |
| 86255 | <1% | 34 | $172.47 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 687 | $157.84 |
| 83020 | <1% | 81 | $153.55 | |
| 84207 | <1% | 76 | $152.22 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 149 | $145.49 |
| 88313 | <1% | 385 | $132.56 | |
| 82652 | <1% | 26 | $117.24 | |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | <1% | 1,913 | $111.60 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 382 | $109.62 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,513 | $103.80 |
| 82040 | <1% | 478 | $101.44 | |
| 83655 | <1% | 27 | $88.27 | |
| 93321 | <1% | 40 | $84.96 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $82.00 |
| 86592 | <1% | 29 | $78.49 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 38 | $74.10 |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | <1% | 28 | $73.66 |
| 84155 | <1% | 103 | $70.58 | |
| 87807 | <1% | 109 | $69.72 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 426 | $64.75 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 458 | $62.89 |
| 82785 | <1% | 12 | $62.29 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 3,059 | $60.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 143 | $58.50 |
| 82677 | <1% | 70 | $55.24 | |
| 86704 | <1% | 13 | $55.11 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 140 | $53.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 126 | $52.21 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 257 | $49.25 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,001 | $48.90 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | <1% | 16 | $41.84 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 533 | $40.81 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 343 | $39.66 |
| 96376 | <1% | 5,301 | $39.02 | |
| 86141 | <1% | 13 | $38.63 | |
| 80183 | <1% | 12 | $36.00 | |
| 76942 | <1% | 33 | $35.84 | |
| 86336 | <1% | 83 | $35.59 | |
| 82107 | <1% | 14 | $35.56 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 183 | $35.40 |
| 82465 | <1% | 13 | $32.35 | |
| 82810 | <1% | 13 | $32.34 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,167 | $31.21 |
| 82010 | <1% | 138 | $28.31 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 90 | $27.38 |
| 80175 | <1% | 13 | $24.51 | |
| 87206 | <1% | 38 | $23.88 | |
| 82164 | <1% | 14 | $18.38 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 384 | $15.03 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,158 | $14.94 |
| 86039 | <1% | 12 | $14.50 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,086 | $14.28 |
| 84520 | <1% | 28 | $11.68 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 344 | $10.29 |
| J1815 | Injection, insulin, per 5 units | <1% | 104 | $2.75 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 12 | $1.47 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 168 | $1.12 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,480 | $0.00 |
| 76827 | 0% | 187 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 671 | $0.00 |
| C1729 | Catheter, drainage | 0% | 210 | $0.00 |
| C1782 | Morcellator | 0% | 303 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 33 | $0.00 |
| 20985 | 0% | 40 | $0.00 | |
| V2630 | Anterior chamber intraocular lens | 0% | 39 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 248 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 479 | $0.00 |
| 64999 | 0% | 13 | $0.00 | |
| 97537 | 0% | 67 | $0.00 | |
| 87634 | 0% | 13 | $0.00 | |
| A4565 | Slings | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 5,009 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 320 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 795 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 14 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 568 | $0.00 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 0% | 73 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 118 | $0.00 |
| 86225 | 0% | 14 | $0.00 | |
| 94660 | 0% | 33 | $0.00 | |
| 85660 | 0% | 24 | $0.00 | |
| C1753 | Catheter, intravascular ultrasound | 0% | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROW, BEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS Detroit Receiving Hospital INC | Detroit, MI | $60.48M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.